Similar to onasemnogene abeparvovec, all plans required patients to have a confirmed diagnosis of SMA based on genetic criteria, e.g. either homozygous deletion or dysfunctional mutation of the SMN1 gene. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.